Navigation Links
Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
Date:5/15/2013

about Boehringer Ingelheim clinical trials in oncology can visit www.inoncologyus.com for additional information. 

About Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim has a demonstrated commitment to corporate social responsibility. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about $19.1 billion (14.7 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

For more information please visit www.us.boehringer-ingelheim.com.

*Afatinib and nintedanib are investigational compounds; their safety and efficacy have not been established.

References 

[1] Wu, Y., MD.  LUX-Lung 6: A randomized, open-label, Phase III study of afatinib (A) vs gemcitabine/cisplatin
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
(Date:7/9/2014)... that sudden, acute episodes of low back pain are ... air pressure, wind direction and precipitation. Findings published in ... the American College of Rheumatology (ACR), indicate that the ... wind speed or wind gusts, but was not clinically ... (WHO) nearly everyone experiences low back pain at some ...
(Date:7/9/2014)... was associated with a small increased risk of prostate ... prostate cancer according to a new study from Harvard ... the association remained even among men who received regular ... cannot be explained by diagnostic bias. It is the ... at the link between vasectomy and prostate cancer. , ...
(Date:7/9/2014)... Susan Wakulich was told she had an aneurysm, she figured ... her. , "I was devastated," said Wakulich, who is 56 ... this was a serious diagnosis. Then I met Dr. Bernard ... a less invasive procedure. It was something I didn,t even ... a multi-center U.S. clinical trial to evaluate the safety and ...
(Date:7/9/2014)... Using an innovative tool that captures heretofore hidden ways ... identified a protein that makes breast cancer cells more ... to trigger cancer,s spread in part by blocking two ... finding that suggests these two disease processes could have ... the July 10 issue of Nature , points ...
(Date:7/9/2014)... scientific research into the metabolism of stromal support cells ... metabolism of these cell types in the development of ... inflammatory conditions and cancer. That was the conclusion of ... Leuven in the leading journal Nature . , ... of wake-up call. The metabolism of cancer cells has ...
Breaking Medicine News(10 mins):Health News:Low back pain? Don't blame the weather 2Health News:Vasectomy may increase risk of aggressive prostate cancer 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Wake-up call for more research into cell metabolism 2
... N.J., Nov. 11 Speedus Corp. (Nasdaq: SPDE ) ... was appointed to the Company,s Board of Directors. , Mr. ... he founded in 1988, and has been a General Partner ... Debt II, L.P. since 2004. Prior to these roles Mr. ...
... Benefit in New Safe ,til Stable Program , MEMPHIS, ... for the outstanding Memphis-based National Bipolar Foundation; a press conference ... Science Center on November 17th at 2pm at the Student ... Foundation has been in the national spotlight during the past ...
... Study finds medication works as well in certain people, ... -- People suffering from blocked renal arteries fare just ... by having the narrowed artery opened and a stent ... chronic kidney disease -- people with severe hypertension -- ...
... ... with an addiction to cocaine. They were also desperate pioneers whose drug use ... to a double-blind, placebo-controlled study to test whether an epilepsy drug could reduce ... were taking a medicine called vigabatrin spent the final three weeks of the ...
... USTeleradiology, LLC,s reaccreditation survey by The Joint Commission ... Joint Commission accreditation - the gold standard within the ... "UST has experienced significant growth over the past ... loyalty of our clients, the dedication of our physicians, ...
... ATLANTA, Nov. 11 This holiday season, Ingenious Med is ... and treasure to roughly 2,000 Metro-Atlanta children living in group ... a Thanksgiving food drive, an effort to stock 129 shelters ... looks to volunteers like Ingenious Med to host these food ...
Cached Medicine News:Health News:Speedus Corp. Names Stephen X. Graham to Board of Directors 2Health News:Memphis Mayor Endorses National Bipolar Foundation 2Health News:Surgery Not Always Best for Narrowed Kidney Arteries 2Health News:Surgery Not Always Best for Narrowed Kidney Arteries 3Health News:Anti-Epileptic Drug Curbs Cocaine Use in First Study Comparing Placebo Dose 2Health News:Anti-Epileptic Drug Curbs Cocaine Use in First Study Comparing Placebo Dose 3Health News:Anti-Epileptic Drug Curbs Cocaine Use in First Study Comparing Placebo Dose 4Health News:USTeleradiology Retains Joint Commission Accreditation 2Health News:Ingenious Med Partners with Children's Restoration Network for Holiday Charity 2
... the needs of the higher risk ... features the PneumaticWalker for Diabetics. Similar ... Diabetics incorporates an innovative dual density ... insole, when combined with the semi-rigid ...
... Sarmiento style Patella-Tendon-Bearing brace is designed for ... tibia and fibula. The tibial crest provides ... medullary nailing and removal of internal or ... of joints above and below the fracture ...
... VACOPED is a revolutionary cast replacement ... the lower leg and foot. , ... patient's anatomy and in conjunction with a ... the general time of fracture or rupture ...
... combines the therapeutic benefits of controlled compression ... to minimize pain. The cuff is anatomically ... maximum cryotherapy.,All Cryo/Cuffs can be ordered as ... (including a tube assembly and insulation disk). ...
Medicine Products: